Combination of EGFR-TKIs and chemotherapy was also suggested by some clinicians as they can delay drug resistance and SCLC transformation, however, safety and efficacy of such combinatorial therapy is still doubtful. This evidence concerns the gene EGFR and small cell lung carcinoma.